Larimar Therapeutics, Inc.

LRMR Healthcare Biotechnology

In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.99 0.00 0.00%
Market cap
$206.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
4.70 4.29 2.19 4.06

+8 more quarters

Net Debt/EBITDA
4.51 6.44 2.14 3.53
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.41 1.51 0.62 0.60
Capex/Depreciation
0.46 0.00 0.00 0.10
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.43) (0.50) (0.53) (0.37)
Cash per Share
1.50 2.23 1.88 2.24
Shareholders Equity per Share
1.23 1.76 1.07 1.78
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
1.23 1.76 1.07 1.78
Free Cash Flow
(44.16) (44.61) (38.53) (28.78)
Working Capital
126.51 157.22 77.23 138.11
Capital Expenditures
(0.13) — 0.00 (0.02)
Net Current Asset Value
122.75 154.50 74.27 134.91
Other line items
Quick Ratio
4.57 4.20 2.11 3.89
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.42) (0.50) (0.53) (0.37)
Capex per Share
0.00 0.00 0.00 0.00
Average Payables
5.88 5.43 3.82 6.39
Average Assets
157.65 189.34 173.03 203.19
Average Common Equity
123.62 151.15 124.95 168.72
Capex to Sales
0.00 — 0.00 0.00

Fold the line items

Columns are period end dates